Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension.
Open Access
- 31 March 1981
- Vol. 45 (4) , 385-388
- https://doi.org/10.1136/hrt.45.4.385
Abstract
An infusion of prostacyclin (PGI2) in four patients with pulmonary hypertension resulted in a dose-related decrease in the systemic and pulmonary vascular resistance and an increase in cardiac output. No selectivity for the pulmonary vasculature was observed and the drug was not therapeutically beneficial.This publication has 20 references indexed in Scilit:
- USE OF PROSTACYCLIN IN PERSISTENT FETAL CIRCULATIONThe Lancet, 1979
- Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension.Heart, 1978
- Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertensionThe American Journal of Cardiology, 1978
- Generation of prostacyclin by lungs in vivo and its release into the arterial circulationNature, 1978
- Diazoxide in treatment of primary pulmonary hypertension.Heart, 1978
- Clinical primary pulmonary hypertension: three pathologic types.Circulation, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Regression of primary pulmonary hypertension.Heart, 1976
- Primary Pulmonary HypertensionCirculation, 1970
- Primary pulmonary hypertension of unusually long duration.Heart, 1970